Cargando…
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy
PURPOSE: The purpose of this clinical study was to be the first to explore whether ART-123, a recombinant human soluble thrombomodulin, prevents oxaliplatin-induced peripheral neuropathy (OIPN). METHODS: This randomized, phase IIa trial enrolled stage II/III colon cancer patients who received adjuva...
Autores principales: | Kotaka, Masahito, Saito, Yoji, Kato, Takeshi, Satake, Hironaga, Makiyama, Akitaka, Tsuji, Yasushi, Shinozaki, Katsunori, Fujiwara, Toshiyoshi, Mizushima, Tsunekazu, Harihara, Yasushi, Nagata, Naoki, Kurihara, Naoto, Ando, Masahiko, Kusakawa, Genichi, Sakai, Takumi, Uchida, Yugo, Takamoto, Mikihiro, Kimoto, Saki, Hyodo, Ichinosuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561567/ https://www.ncbi.nlm.nih.gov/pubmed/32965539 http://dx.doi.org/10.1007/s00280-020-04135-8 |
Ejemplares similares
-
Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
por: Ishibashi, Keiichiro, et al.
Publicado: (2021) -
Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database
por: Shinozaki, Eiji, et al.
Publicado: (2021) -
Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer
por: Satake, Hironaga, et al.
Publicado: (2022) -
First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study
por: Satake, Hironaga, et al.
Publicado: (2017) -
Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
por: Satake, Hironaga, et al.
Publicado: (2020)